Medical Editor: John P. Cunha, DO, FACOEP
Premarin Intravenous (conjugated estrogens) for Injection is a form of a female hormone used to treat abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology. Premarin Intravenous is indicated for short-term use only, to provide a rapid and temporary increase in estrogen levels. Premarin Intravenous is available in generic form. Common side effects of Premarin Intravenous include:
- abdominal cramps
- stomach pain
- back pain
- joint pain
- irregular vaginal bleeding
- vaginal spotting
- loss of periods or excessively prolonged periods
- breast pain
- breast enlargement or tenderness
- hair loss, and
- changes in sexual drive.
For treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology the dose of Premarin Intravenous is one 25 mg injection, intravenously or intramuscularly. Premarin Intravenous may interact with blood thinners, rifampin, barbiturates, carbamazepine, griseofulvin, phenytoin, St. John's wort, primidone, erythromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice. Tell your doctor all medications and supplements you use. Premarin Intravenous should not be used during pregnancy. Premarin Intravenous may decease the quality and quantity of breast milk produced. Consult your doctor before breastfeeding.
Our Premarin Intravenous (conjugated estrogens) for Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Premarin Intravenous for injection is indicated for short-term use. However, the warnings, precautions and adverse reactions associated with oral Premarin treatment should be taken into account.
The following adverse reactions have been identified during post-approval use of oral or intravenous Premarin. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Abnormal uterine bleeding/spotting.
Dysmenorrhea or pelvic pain.
Increase in size of uterine leiomyomata.
Vaginitis, including vaginal candidiasis.
Change in amount of cervical secretion.
Change in cervical ectropion.
Retinal vascular thrombosis.
Intolerance to contact lenses.
Central Nervous System
Increase or decrease in weight.
Aggravation of porphyria.
Changes in libido.
Hypocalcemia (preexisting condition).
Injection site pain.
Injection site edema.
Phlebitis (injection site).
Exacerbation of asthma.
Read the entire FDA prescribing information for Premarin Injection (Conjugated Estrogens for Injection)